BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)

Leukemia

Volumn 14, Issue 5, 2000, Pages 816-825

  Porwit MacDonald, A ^a   Bjorklund E ^a   Lucio, P ^b   Van Lochem, E G ^c,d   Mazur, J ^a,h   Parreira, A ^b   Van Den Beemd, M W M ^c,d   Van Wering, E R ^e   Baars, E ^e   Gaipa, G ^f   Biondi, A ^f   Ciudad, J ^g   Van Dongen, J J M ^c,d   San Miguel, J F ^g   Orfao, A ^g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^f Avancorpo Sett C Piano Terra   (Italy)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

Acute lymphoblastic leukemia; Bone marrow; Flow cytometry; Immunophenotype; Minimal residual disease; T cells

Indexed keywords

CD2 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; FLUORESCEIN ISOTHIOCYANATE; PHYCOERYTHRIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL TRANSFORMATION; CHILD; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOCYTE SUBPOPULATION;

EID: 0342748605     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401741     Document Type: Article

References (38)

1. Janossy G, Bollum FJ, Bradstock KF, Ashley J. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood 1980; 56: 430-441.
2. van Dongen JJ, Krissansen GW, Wolvers-Tettero IL, Comans-Bitter WM, Adriaansen HJ, Hooijkaas H, van Wering ER, Terhorst C. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood 1988; 71: 603-612.
3. Ludwig WD, Harbott J, Bartram CR, Komischke B, Sperling C, Teichmann JV, Seibt-Jung H, Notter M, Odenwald E, Nehmer A. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Rec Res Cancer Res 1993; 131: 269-282.
4. van Dongen JJ, Adriaansen HJ. Immunobiology of leukemia. In: Henderson ES, Lister TA, Greaves MF (eds). Leukemia, 6th edn, WB Saunders: Philadelphia, 1996, pp 83-130.
5. Campana D, Coustan-Smith E, Behm FG. The definition of remission in acute leukemia with immunologic techniques. Bone Marrow Transplant 1991; 8: 429-437.
6. van Dongen JJ, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerise chain reaction. Leukemia 1992; 6 (Suppl. 1): 47-59.
7. Drach J, Drach D, Glassl H, Gattringer C, Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13: 893-901.
8. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance (see comments). Blood 1995; 85: 1416-1434.
9. Orfao A, Ciudad J, Lopez-Berges MC, Lopez A, Vidriales B, Caballero MD, Valverde B, Gonzalez M, San Miguel JF. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma 1994; 13 (Suppl 1): 87-90.
10. van Dongen IJ, Szczepanski T, de Bruijn MA, van den Beemd MW, de Bruin-Versteeg S, Wijkhuijs JM, Tibbe GJ, van Gastel-Mol EI, Groeneveld K, Hooijkaas H. Detection of minimal residual disease in acute leukemia patients. Cytok Mol Ther 1996; 2: 121-133.
11. Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernandez J, Moro MJ, Mateos MV, Orfao A. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 3774-3781.
12. Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JJ, San Miguel JF. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999; 13: 419-427.
13. Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13: 558-567.
14. van Lochem EG, Groeneveld K, te Marvelde JG, van den Beemd MW, Hooijkaas H, van Dongen JJ. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes: testing of a new fixation-permeabilization solution (letter). Leukemia 1997; 11: 2208-2210.
15. Groeneveld K, te Marvelde JG, van den Beemd MW, Hooijkaas H, van Dongen JJ. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Leukemia 1996; 10: 1383-1389.
16. Barcena A, Muench MO, Roncarolo MG, Spits H. Tracing the expression of CD7 and other antigens during T and myeloid cell differentiation in the human fetal liver and thymus. Leuk Lymphoma 1995; 17: 1-11.
17. + linkeage cells in human thymic organ culture. J Exp Med 1994; 180: 123-132.
18. Schmitt C, Ktorza S, Sarun S, Verpilleux MP, Blanc C, Deugnier MA, Dalloul A, Debre P. CD34-positive early stages of human T-cell differentiation. Leuk Lymphoma 1995; 17: 43-50.
19. dim cells in the human thymus can differentiate into T, natural killer, and dendritic cells but are distinct from pluripotent stem cells. Blood 1996; 87: 5196-5206.
20. Spits H, Blom B, Jaleco AC, Weijer K, Verschuren MC, van Dongen JJ, Heemskerk MH, Res PC. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev 1998; 165: 75-86.
21. + progenitors capable of developing into T cells are not committed to the T cell lineage. J Immunol 1997; 158: 3571-3577.
22. Lazarovits AI, Osman M, Le Feuvre CE, Ley SC, Crumpton MJ. CD7 is associated with CD3 and CD45 on human T cells. J Immunol 1994; 153: 3956-3966.
23. Ginaldi L, Farahat N, Matutes E, De Martinis M, Morilla R, Catovsky D. Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry. J Clin Pathol 1996; 49: 539-544.
24. van Wering ER, Beishuizen A, Roeffen ET, van der Linden-Schrever BE, Verhoeven MA, Hahlen K, Hooijkas H, van Dongen JJ. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1523-1533.
25. van Dongen JJ, Hooijkaas H, Comans-Bitter M, Hahlen K, de Klein A, van Zanen GE, van't Veer MB, Abels J, Benner R. Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), HLA-DR, and a T cell marker may represent prothymocytes. J Immunol 1985; 135: 3144-3150.
26. Bender JG, Unverzagt KL, Walker DE, Lee W, Van Epps DE, Smith DH, Stewart CC, To LB. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 1991; 77: 2591-2596.
27. Long H, Gaffney P, Mortari F, Miller JS. CD3 gamma, CD3 delta, and CD3 zeta mRNA in adult human marrow hematopoietic progenitors correlates with surface CD2 and CD7 expression. Exp Hematol 1996; 24: 1402-1408.
28. Campana D, Thompson JS, Amlot P, Brown S, Janossy G. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. J Immunol 1987; 138: 648-655.
29. Caver TE, Slobod KS, Flynn PM, Behm FC, Hudson MM, Turner EV, Webster RG, Boyett JM, Tassie TL, Pui CH, Hurwitz JL. Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 619-622.
30. Pui CH, Rubnitz IE, Hancock ML, Downing JR, Raimondi SC, Rivera GK, Sandlund JT, Ribeiro RC, Head DR, Relling MW, Evans WE, Behm FG. Reappraisal of the clinical and biological significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 3768-3773.
31. Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG, Nachman J, Steinherz PG, Sensel MG, Reaman GH. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997; 90: 28-35.
32. Babusikova O, Glasova M, Konikova E, Kusenda J, Cap J, Gyarfas J, Koubek K. Phenotypic heterogeneity and aberrant markers expression in T-cell leukemia. Neoplasma 1998; 45: 128-134.
33. Boldt DH, Kopecky KJ, Head D, Gehly G, Radich JP, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia 1994; 8: 2118-2126.
34. Ryan D, Kossover S, Mitchell S, Frantz C, Hennessy L, Cohen H. Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identitied by hematopoietic differentiation antigens. Blood 1986; 68: 417-425.
35. Hurwitz CA, Loken MR, Graham ML, Karp JE, Borowitz MJ, Pullen DJ, Civin CI. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 1998; 72: 299-307.
36. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, O'Brien MC, Baron S, Deisseroth AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
37. Terstappen LW, Safford M, Unterhalt M, Konemann S, Zurlutter K, Piechotka K, Drescher M, Aul C, Buchner T, Hiddemann W. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992; 6: 993-1000.
38. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Cameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grumayer ER, Blondi A, San Miguel JF, van Dongen JJ. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118.